RS55742B2 - Dihidrat benzotiofenskog jedinjenja i proces za njegovu proizvodnju - Google Patents
Dihidrat benzotiofenskog jedinjenja i proces za njegovu proizvodnjuInfo
- Publication number
- RS55742B2 RS55742B2 RS20170214A RSP20170214A RS55742B2 RS 55742 B2 RS55742 B2 RS 55742B2 RS 20170214 A RS20170214 A RS 20170214A RS P20170214 A RSP20170214 A RS P20170214A RS 55742 B2 RS55742 B2 RS 55742B2
- Authority
- RS
- Serbia
- Prior art keywords
- ppm
- dihydrate
- disorder
- quinolin
- spectrum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636920P | 2012-04-23 | 2012-04-23 | |
| US201361791378P | 2013-03-15 | 2013-03-15 | |
| EP13722129.7A EP2841431B2 (en) | 2012-04-23 | 2013-04-23 | Dihydrate of benzothiophene compound and process for producing the same |
| PCT/JP2013/062681 WO2013162046A1 (en) | 2012-04-23 | 2013-04-23 | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RS55742B1 RS55742B1 (sr) | 2017-07-31 |
| RS55742B2 true RS55742B2 (sr) | 2024-04-30 |
Family
ID=48428584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20170214A RS55742B2 (sr) | 2012-04-23 | 2013-04-23 | Dihidrat benzotiofenskog jedinjenja i proces za njegovu proizvodnju |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US9499525B2 (OSRAM) |
| EP (1) | EP2841431B2 (OSRAM) |
| JP (1) | JP5952917B2 (OSRAM) |
| KR (1) | KR102160395B1 (OSRAM) |
| CN (1) | CN104254530B (OSRAM) |
| AR (1) | AR090774A1 (OSRAM) |
| AU (1) | AU2013253372B2 (OSRAM) |
| BR (1) | BR112014026424B1 (OSRAM) |
| CA (1) | CA2870000C (OSRAM) |
| CO (1) | CO7111315A2 (OSRAM) |
| CY (1) | CY1119103T1 (OSRAM) |
| DK (1) | DK2841431T4 (OSRAM) |
| EA (1) | EA026541B1 (OSRAM) |
| ES (1) | ES2617881T5 (OSRAM) |
| FI (1) | FI2841431T4 (OSRAM) |
| HR (1) | HRP20170242T4 (OSRAM) |
| HU (1) | HUE031997T2 (OSRAM) |
| IL (1) | IL235044B (OSRAM) |
| IN (1) | IN2014DN08867A (OSRAM) |
| JO (1) | JO3325B1 (OSRAM) |
| LT (1) | LT2841431T (OSRAM) |
| ME (1) | ME02619B (OSRAM) |
| MX (1) | MX361723B (OSRAM) |
| MY (1) | MY170220A (OSRAM) |
| NZ (1) | NZ630260A (OSRAM) |
| PH (1) | PH12014502324A1 (OSRAM) |
| PL (1) | PL2841431T5 (OSRAM) |
| PT (1) | PT2841431T (OSRAM) |
| RS (1) | RS55742B2 (OSRAM) |
| SG (1) | SG11201406790VA (OSRAM) |
| SI (1) | SI2841431T2 (OSRAM) |
| SM (2) | SMT201700130T1 (OSRAM) |
| TW (1) | TWI562991B (OSRAM) |
| UA (1) | UA117456C2 (OSRAM) |
| WO (1) | WO2013162046A1 (OSRAM) |
| ZA (1) | ZA201407477B (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JOP20210047A1 (ar) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه |
| MX2016013889A (es) * | 2014-04-22 | 2017-03-09 | Otsuka Pharma Co Ltd | Medicamento. |
| CN104447723A (zh) * | 2014-11-28 | 2015-03-25 | 瑞阳制药有限公司 | 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法 |
| CN104829603A (zh) * | 2015-05-19 | 2015-08-12 | 杭州新博思生物医药有限公司 | A晶型依匹唑派盐酸盐及其制备方法 |
| CN106883223B (zh) * | 2015-12-16 | 2021-11-23 | 北京福元医药股份有限公司 | 一种Brexpiprazole盐酸盐的纯化方法 |
| WO2017106641A1 (en) | 2015-12-17 | 2017-06-22 | Assia Chemical Industries Ltd. | Solid state forms of brexpiprazole |
| US10464931B2 (en) | 2015-12-28 | 2019-11-05 | Honour (R&D) | Process for the preparation of Quinolin-2(1H)-one derivatives |
| JP2019059672A (ja) * | 2015-12-28 | 2019-04-18 | 大日本住友製薬株式会社 | 治療抵抗性うつ病等の治療薬 |
| US10501450B2 (en) | 2016-02-01 | 2019-12-10 | Hexal Ag | Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations |
| US20170320862A1 (en) | 2016-05-03 | 2017-11-09 | Cadila Healthcare Limited | Process for the preparation of brexpiprazole and intermediates thereof |
| CN107365305A (zh) * | 2016-05-12 | 2017-11-21 | 上海奥博生物医药技术有限公司 | 一种依匹哌唑新晶型及其制备方法 |
| WO2017208251A1 (en) * | 2016-05-31 | 2017-12-07 | Cipla Limited | A new stable polymorph of brexpiprazole and process for preparation thereof |
| CN106188023A (zh) * | 2016-07-04 | 2016-12-07 | 山东川成医药股份有限公司 | 一种依匹唑派的精制方法 |
| PL233778B1 (pl) | 2016-07-19 | 2019-11-29 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu |
| WO2018033484A1 (en) | 2016-08-16 | 2018-02-22 | Hexal Aktiengesellschaft | Pharmaceutical compositions of a benzothiophene compound |
| US11123300B2 (en) | 2016-08-16 | 2021-09-21 | Hexal Ag | Immediate release tablet of a benzothiophene compound |
| CN107936005A (zh) * | 2016-10-13 | 2018-04-20 | 上海科胜药物研发有限公司 | 一种依匹哌唑新晶型ii及其制备方法 |
| CN111233848A (zh) * | 2016-12-14 | 2020-06-05 | 上海博志研新药物技术有限公司 | 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用 |
| US11072605B2 (en) | 2017-02-02 | 2021-07-27 | Hexal Ag | Crystalline brexpiprazole |
| EP3501506B1 (en) | 2017-12-19 | 2019-10-09 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
| CN111440158A (zh) * | 2020-03-24 | 2020-07-24 | 石药集团中奇制药技术（石家庄）有限公司 | 一种盐酸依匹哌唑新晶型及其制备方法 |
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| WO2022176017A1 (ja) * | 2021-02-16 | 2022-08-25 | 大塚製薬株式会社 | 非晶質体及び当該非晶質体を含む組成物 |
| WO2023067664A1 (ja) * | 2021-10-18 | 2023-04-27 | 大塚製薬株式会社 | ベンゾチオフェン化合物の新規結晶形及びその製造方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| MXPA06004489A (es) † | 2003-10-23 | 2006-06-20 | Otsuka Pharma Co Ltd | Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada. |
| EP1797039A1 (en) | 2004-09-13 | 2007-06-20 | Matrix Laboratories Ltd | Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
| JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| PE20090387A1 (es) * | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
| JP2011500090A (ja) * | 2007-10-26 | 2011-01-06 | レプリジェン コーポレイション | 神経障害に役立つヒストンデアセチラーゼ・インヒビターを確認する方法 |
| PT2247282E (pt) * | 2008-01-30 | 2014-11-11 | Novartis Ag | Formulação de libertação controlada compreendendo octreotido e três polímeros lineares de polilactido-coglicolido |
| EP2233471A1 (en) * | 2009-02-06 | 2010-09-29 | Adamed Sp. z o.o. | A salt of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4.dihydro-2(1h)-quinolinone with 5-sulfosalicylic acid and its preparation process |
| AR082494A1 (es) † | 2010-08-24 | 2012-12-12 | Otsuka Pharma Co Ltd | Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona |
| EP3156056B1 (en) * | 2011-03-18 | 2023-12-06 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
| JP2012232958A (ja) * | 2011-05-09 | 2012-11-29 | Otsuka Pharmaceut Co Ltd | 注射製剤 |
| KR101911121B1 (ko) * | 2011-07-28 | 2018-10-23 | 오쓰까 세이야꾸 가부시키가이샤 | 벤조［ｂ］티오펜 화합물의 제조 방법 |
| JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
-
2013
- 2013-04-19 TW TW102114005A patent/TWI562991B/zh active
- 2013-04-22 AR ARP130101319A patent/AR090774A1/es unknown
- 2013-04-23 LT LTEP13722129.7T patent/LT2841431T/lt unknown
- 2013-04-23 NZ NZ630260A patent/NZ630260A/en unknown
- 2013-04-23 KR KR1020147032745A patent/KR102160395B1/ko active Active
- 2013-04-23 EP EP13722129.7A patent/EP2841431B2/en active Active
- 2013-04-23 US US14/396,224 patent/US9499525B2/en active Active
- 2013-04-23 PL PL13722129.7T patent/PL2841431T5/pl unknown
- 2013-04-23 HR HRP20170242TT patent/HRP20170242T4/hr unknown
- 2013-04-23 BR BR112014026424-4A patent/BR112014026424B1/pt active IP Right Grant
- 2013-04-23 SM SM20170130T patent/SMT201700130T1/it unknown
- 2013-04-23 WO PCT/JP2013/062681 patent/WO2013162046A1/en not_active Ceased
- 2013-04-23 CN CN201380021622.6A patent/CN104254530B/zh active Active
- 2013-04-23 EA EA201491933A patent/EA026541B1/ru not_active IP Right Cessation
- 2013-04-23 DK DK13722129.7T patent/DK2841431T4/da active
- 2013-04-23 ME MEP-2017-56A patent/ME02619B/me unknown
- 2013-04-23 RS RS20170214A patent/RS55742B2/sr unknown
- 2013-04-23 SG SG11201406790VA patent/SG11201406790VA/en unknown
- 2013-04-23 MX MX2014012527A patent/MX361723B/es active IP Right Grant
- 2013-04-23 IN IN8867DEN2014 patent/IN2014DN08867A/en unknown
- 2013-04-23 CA CA2870000A patent/CA2870000C/en active Active
- 2013-04-23 PT PT137221297T patent/PT2841431T/pt unknown
- 2013-04-23 MY MYPI2014703139A patent/MY170220A/en unknown
- 2013-04-23 JO JOP/2013/0114A patent/JO3325B1/ar active
- 2013-04-23 UA UAA201412555A patent/UA117456C2/uk unknown
- 2013-04-23 FI FIEP13722129.7T patent/FI2841431T4/fi active
- 2013-04-23 SI SI201330538T patent/SI2841431T2/sl unknown
- 2013-04-23 AU AU2013253372A patent/AU2013253372B2/en active Active
- 2013-04-23 ES ES13722129T patent/ES2617881T5/es active Active
- 2013-04-23 HU HUE13722129A patent/HUE031997T2/en unknown
- 2013-04-23 JP JP2014550214A patent/JP5952917B2/ja active Active
-
2014
- 2014-10-07 IL IL235044A patent/IL235044B/en active IP Right Grant
- 2014-10-14 CO CO14226629A patent/CO7111315A2/es unknown
- 2014-10-15 ZA ZA2014/07477A patent/ZA201407477B/en unknown
- 2014-10-17 PH PH12014502324A patent/PH12014502324A1/en unknown
-
2016
- 2016-10-14 US US15/294,644 patent/US10407415B2/en active Active
-
2017
- 2017-02-28 SM SM201700130T patent/SMT201700130B/it unknown
- 2017-03-07 CY CY20171100293T patent/CY1119103T1/el unknown
-
2019
- 2019-09-09 US US16/564,972 patent/US20200140424A1/en not_active Abandoned
-
2020
- 2020-08-04 US US16/985,177 patent/US20210115030A1/en not_active Abandoned
-
2022
- 2022-02-14 US US17/651,042 patent/US20230049327A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230049327A1 (en) | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same | |
| TWI637949B (zh) | 胺基三衍生物及含有其等之醫藥組合物 | |
| EP3423443B1 (en) | Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors | |
| WO2011035209A1 (en) | Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same | |
| CN108503627A (zh) | 用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用 | |
| KR20140036312A (ko) | Ｐａｒｐ 저해 활성을 갖는 신규 화합물 | |
| KR20130025857A (ko) | 2-［［［2-［(히드록시아세틸)아미노］-4-피리디닐］메틸］티오］-ｎ-［4-(트리플루오로메톡시)페닐］-3-피리딘카르복사미드의 벤젠술폰산염, 이의 결정, 이의 결정 다형 및 이들의 제조 방법 | |
| WO2024099478A1 (zh) | 可吸入型芳环并噻嗪及类似物、含其的药物组合物及其在抗炎、抗肿瘤中的应用 | |
| WO2019001307A1 (zh) | 一种酰胺类化合物及包含该化合物的组合物及其用途 | |
| HK1203073B (en) | Dihydrate of benzothiophene compound and process for producing the same | |
| CA3110788A1 (en) | Combination therapy for the treatment of estrogen-receptor positive breast cancer | |
| CA3101143A1 (en) | Salt form | |
| HK40079891A (en) | Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists | |
| KR20200099014A (ko) | 실로스타졸의 제조방법 및 이를 포함하는 약학제제 | |
| JP2024526198A (ja) | Ｒｏｎ阻害剤としての新規なウレア誘導体化合物 | |
| EP4021574A1 (en) | Modulators of circadian rhythms and uses thereof | |
| JP2000309586A (ja) | ６−置換−７−ヘテロキノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法 |